Drugs / INO-4201
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04906629 | Sep 2021 → Jan 2022 | Ebola hemorrhagic fever | University of Geneva, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT02464670 | May 2015 → May 2018 | Ebola hemorrhagic fever | Inovio Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2023-05-10 | Inovio Pharmaceuticals | Results INOVIO Reports First Quarter 2023 Financial Results and Operational Highlights inovio.com ↗
INO-4201 was well-tolerated and boosted humoral responses in 36 of 36 (100%) treated participants |
| 2023-04-17 | Inovio Pharmaceuticals | Results Data from Phase 1b trial with INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) presented at ECCMID 2023 inovio.com ↗
Today, the full data set was presented at |
| 2023-02-02 | Inovio Pharmaceuticals | Results INOVIO Reports Positive Phase 1b Results for INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) inovio.com ↗
In the trial, INO-4201 was well-tolerated and boosted humoral responses in 100% (36 of 36) of treated participants. |
| 2019-03-21 | Inovio Pharmaceuticals | Results Inovio's Ebola Vaccine Delivered Intradermally Demonstrates 100% Immunogenicity in a Clinical Study Published in The Journal of Infectious Diseases inovio.com ↗
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that its Ebola vaccine, INO-4201, was safe, tolerable, and generated strong T cell and antibody responses. |
| 2017-04-11 | Inovio Pharmaceuticals | Results Inovio Ebola Vaccine Demonstrates Robust Immune Responses with Favorable Safety Profile in Expanded Clinical Trial inovio.com ↗
The results across both stages of the trial, including both intramuscular and intradermal delivery, demonstrated that 95% (170/179) of evaluable subjects generated an Ebola-specific antibody immune response, with the mean antibody titer comparable or superior to those reported from viral vector-based Ebola vaccines. |
All press releases naming this drug 7 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INO-4201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04906629 ↗ |
| Modality | Vaccine | “Two DNA vaccine candidates (INO-4201 and INO-4202) targeting the EBOV glycoprotein (GP) were evaluated for safety, tolerability, and immunogenicity in a phase 1 clinical trial.” PMID 30891607 ↗ Jul 2019 |
| Route | Intramuscular | “INO-4201 delivered IM followed by Electroporation” NCT02464670 ↗ |